AZD-2389
- Generic Name
- AZD-2389
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
Phase 1
Not yet recruiting
- Conditions
- Advanced Chronic Liver DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06974565
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
Phase 1
Recruiting
- Conditions
- Advanced Chronic Liver DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06973005
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06846528
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06812780
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06750276
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 126
- Registration Number
- NCT06138795
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath